-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
GreenLight Biosciences (NASDAQ:GRNA) and ITeos Therapeutics (NASDAQ:ITOS) Financial Contrast
GreenLight Biosciences (NASDAQ:GRNA) and ITeos Therapeutics (NASDAQ:ITOS) Financial Contrast
GreenLight Biosciences (NASDAQ:GRNA – Get Rating) and iTeos Therapeutics (NASDAQ:ITOS – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends and earnings.
Volatility & Risk
GreenLight Biosciences has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, iTeos Therapeutics has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500.
Get GreenLight Biosciences alerts:Analyst Recommendations
This is a breakdown of recent ratings and target prices for GreenLight Biosciences and iTeos Therapeutics, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
GreenLight Biosciences | 0 | 0 | 3 | 0 | 3.00 |
iTeos Therapeutics | 0 | 0 | 0 | 0 | N/A |
Valuation and Earnings
This table compares GreenLight Biosciences and iTeos Therapeutics' gross revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
GreenLight Biosciences | N/A | N/A | -$15.06 million | N/A | N/A |
iTeos Therapeutics | $344.77 million | 2.18 | $214.52 million | $6.88 | 3.08 |
iTeos Therapeutics has higher revenue and earnings than GreenLight Biosciences.
Profitability
This table compares GreenLight Biosciences and iTeos Therapeutics' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
GreenLight Biosciences | N/A | -195.71% | -45.30% |
iTeos Therapeutics | 57.48% | 42.62% | 31.39% |
Institutional & Insider Ownership
23.9% of GreenLight Biosciences shares are owned by institutional investors. Comparatively, 94.7% of iTeos Therapeutics shares are owned by institutional investors. 6.5% of iTeos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
iTeos Therapeutics beats GreenLight Biosciences on 8 of the 10 factors compared between the two stocks.
About GreenLight Biosciences
(Get Rating)
GreenLight Biosciences Holdings, a biotechnology company, manufactures and sells ribonucleic acid (RNA) products for human health and agriculture applications. Its products for human health include mRNA vaccines and therapeutics; and agricultural RNA products to protect honeybees and crops. The company was founded in 2008 and is headquartered in Medford, Massachusetts.
About iTeos Therapeutics
(Get Rating)
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for GreenLight Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GreenLight Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
GreenLight Biosciences (NASDAQ:GRNA – Get Rating) and iTeos Therapeutics (NASDAQ:ITOS – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends and earnings.
綠光生物(納斯達克:GRNA-GET評級)和ITOS治療(納斯達克:ITOS-GET評級)都是小盤醫療公司,但哪隻股票更優?我們將根據分析師的建議、盈利能力、風險、估值、機構所有權、股息和收益對這兩家公司進行比較。
Volatility & Risk
波動性與風險
GreenLight Biosciences has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, iTeos Therapeutics has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500.
綠光生物科技的貝塔係數為1.33,這意味着其股價的波動性比標準普爾500指數高出33%。相比之下,iTeos Treateutics的貝塔係數為1.42,這意味着其股價的波動性比標準普爾500指數高42%。
Analyst Recommendations
分析師建議
This is a breakdown of recent ratings and target prices for GreenLight Biosciences and iTeos Therapeutics, as provided by MarketBeat.
這是由MarketBeat提供的綠光生物科學公司和iTeos治療公司最近的評級和目標價格細目。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
GreenLight Biosciences | 0 | 0 | 3 | 0 | 3.00 |
iTeos Therapeutics | 0 | 0 | 0 | 0 | N/A |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
綠光生物科學 | 0 | 0 | 3 | 0 | 3.00 |
ITeos治療公司 | 0 | 0 | 0 | 0 | 不適用 |
Valuation and Earnings
估值和收益
This table compares GreenLight Biosciences and iTeos Therapeutics' gross revenue, earnings per share (EPS) and valuation.
此表比較了Greenlight Biosciences和iTeos Treeutics的毛收入、每股收益(EPS)和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
GreenLight Biosciences | N/A | N/A | -$15.06 million | N/A | N/A |
iTeos Therapeutics | $344.77 million | 2.18 | $214.52 million | $6.88 | 3.08 |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
綠光生物科學 | 不適用 | 不適用 | -1,506萬元 | 不適用 | 不適用 |
ITeos治療公司 | 3.4477億美元 | 2.18 | 2.1452億美元 | $6.88 | 3.08 |
iTeos Therapeutics has higher revenue and earnings than GreenLight Biosciences.
ITeos治療公司的收入和收益高於綠光生物科學公司。
Profitability
盈利能力
This table compares GreenLight Biosciences and iTeos Therapeutics' net margins, return on equity and return on assets.
下表比較了綠光生物科學公司和iTeos治療公司的淨利潤率、股本回報率和資產回報率。
Net Margins | Return on Equity | Return on Assets | |
GreenLight Biosciences | N/A | -195.71% | -45.30% |
iTeos Therapeutics | 57.48% | 42.62% | 31.39% |
淨利潤率 | 股本回報率 | 資產回報率 | |
綠光生物科學 | 不適用 | -195.71% | -45.30% |
ITeos治療公司 | 57.48% | 42.62% | 31.39% |
Institutional & Insider Ownership
機構與內部人持股
23.9% of GreenLight Biosciences shares are owned by institutional investors. Comparatively, 94.7% of iTeos Therapeutics shares are owned by institutional investors. 6.5% of iTeos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
綠光生物科技23.9%的股份由機構投資者持有。相比之下,iTeos治療公司94.7%的股份由機構投資者持有。ITeos治療公司6.5%的股份由內部人士持有。強大的機構持股表明,捐贈基金、對衝基金和大型基金管理公司相信,一家公司的長期表現將好於大盤。
Summary
摘要
iTeos Therapeutics beats GreenLight Biosciences on 8 of the 10 factors compared between the two stocks.
ITeos治療公司在兩隻股票之間的10個因素中有8個擊敗了綠光生物科學公司。
About GreenLight Biosciences
關於綠光生物科學
(Get Rating)
(獲取評級)
GreenLight Biosciences Holdings, a biotechnology company, manufactures and sells ribonucleic acid (RNA) products for human health and agriculture applications. Its products for human health include mRNA vaccines and therapeutics; and agricultural RNA products to protect honeybees and crops. The company was founded in 2008 and is headquartered in Medford, Massachusetts.
綠光生物科技控股公司是一家生物技術公司,生產和銷售用於人類健康和農業應用的核糖核酸(RNA)產品。它的人類健康產品包括信使核糖核酸疫苗和治療藥物,以及保護蜜蜂和農作物的農業核糖核酸產品。該公司成立於2008年,總部設在馬薩諸塞州的梅德福德。
About iTeos Therapeutics
關於iTeos治療公司
(Get Rating)
(獲取評級)
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
ITeos治療公司是一家臨牀階段的生物製藥公司,致力於為患者發現和開發免疫腫瘤療法。該公司的產品線包括處於第二階段臨牀試驗的腺苷A2AR拮抗劑的小分子拮抗劑InupAdant,以及處於第1/2階段臨牀試驗的TIGIT或具有Ig和ITIM結構域的T細胞免疫受體拮抗劑EOS-448,以及用於激活樹突狀細胞和巨噬細胞並促進抗體依賴的細胞毒性或ADCC活性的Fc?R。ITeos治療公司成立於2011年,總部設在馬薩諸塞州沃特敦。
Receive News & Ratings for GreenLight Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GreenLight Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《綠光生物科學日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Greenlight Biosciences和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧